[Effectiveness of new diagnostic drug Diaskintest in children for tuberculosis diagnostic].
DST was ascertained to have a high sensitivity in virtually all patients with tuberculosis and a positive reaction was first noted in the infected. With stabilization and regression, the response to DST was much less pronounced than that in clinical and primary infection (that to the Mantoux test being more evident). DST showed its use as a marker of active tuberculosis not only in its local forms, but also in latent tuberculous infection. This makes it possible to apply DST when preventive treatment is performed. The agent may be used to monitor the progress of treatment. DST has a high specificity--healthy individuals had a negative response to DST while the Mantoux test was positive in many cases. The high specificity of DST was suggested by the fact that the persons vaccinated with (this caused BCG ostitis) had a negative reaction to DST while the Mantoux test was positive in all cases BCG-vaccinated BCG. The findings warrant the use of DST for the differential diagnosis of tuberculosis and BCG-associated complications and the possibility of differentiating postvaccinal and infection allergy in children and adolescents.
Litvinov
V I
VI
Shuster
A M
AM
Slogotskaia
L V
LV
Sel'tsovskiĭ
P P
PP
Ovsiankina
E S
ES
Mushkin
A Iu
AIu
Vinogradova
T I
TI
Levi
D T
DT
Bocharova
I V
IV
Filippov
A V
AV
Stakheeva
L B
LB
D000293:Adolescent; D001426:Bacterial Proteins; D015415:Biomarkers; D002648:Child; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011994:Recombinant Proteins; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012882:Skin Tests / Q000379:methods*; D014376:Tuberculosis / Q000175:diagnosis* / Q000382:microbiology
D001426:Bacterial Proteins; D015415:Biomarkers; C117940:CFP-10 protein, Mycobacterium tuberculosis; D011994:Recombinant Proteins